A Breakthrough Approach to Cancer Detection

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. 


The DNA methylome is a rich source of information about human disease. 

Adela’s genome-wide methylome enrichment platform efficiently captures information from the entire methylome, maximizing test performance and improving treatment decisions.

This comprehensive view of the methylome significantly increases the opportunities for Adela’s products to detect cancer signals in the blood compared to approaches that target a smaller set of genomic regions. 

It also enables enhanced prognostic and predictive abilities, as well as dynamic monitoring in patients over time. 

Adela’s platform is being developed for minimal residual disease (MRD) monitoring - with a tissue agnostic approach - and multi-cancer early detection (MCED).


Sensitive tumour detection and classification using plasma cell-free DNA methylomes

read more

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

read more

Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes

read more

Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA

read more

Tumor-naïve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma

read more